MARKET

SPPI

SPPI

Spectrum Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.320
-0.110
-4.53%
Pre Market: 2.330 +0.01 +0.43% 06:48 09/21 EDT
OPEN
2.528
PREV CLOSE
2.430
HIGH
2.530
LOW
2.320
VOLUME
4.43K
TURNOVER
--
52 WEEK HIGH
5.24
52 WEEK LOW
2.145
MARKET CAP
380.65M
P/E (TTM)
-1.8003
1D
5D
1M
3M
1Y
5Y
Hot Stocks: Chinese stocks fall; LI lowers deliveries guidance; MRTX, SPPI data
The major U.S. equity averages saw significant weakness in Monday's pre-market trading, led lower by a drop in Chinese stocks. JD.com, Inc. (NASDAQ:JD), Alibaba (NYSE:BABA) and Baidu (NASDAQ:BIDU) were among
Seekingalpha · 22h ago
SDC, EDSA and APRE among pre market gainers
ZIVO Bioscience (NASDAQ:ZIVO) +175%. Verastem (NASDAQ:VSTM) +22% Oncology's VS-6766 + defactinib combo shows promising action in ovarian cancer study Edesa Biotech (NASDAQ:EDSA) +33% announces positive phase 2 data of its monoclonal antibody in
Seekingalpha · 22h ago
24 Stocks Moving in Monday's Pre-Market Session
Gainers Verastem, Inc. (NASDAQ: VSTM) rose 30.8% to $3.61 in pre-market trading after the company announced a mini oral presentation highlighting updated data from the ongoing investigator-sponsored Phase 1/2 FRAME study.
Benzinga · 23h ago
Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021
HENDERSON, Nev., September 18, 2021--Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data at ESMO Congress 2021.
Business Wire · 2d ago
Spectrum Pharmaceuticals Announces Late-Breaking Oral Presentation of Data for Poziotinib in First-Line NSCLC Patients with HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2021
HENDERSON, Nev., September 13, 2021--Spectrum Pharmaceuticals Announces Late-Breaking Oral Presentation of Data for Poziotinib at the Upcoming ESMO Congress 2021
Business Wire · 09/13 11:00
ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case - SPPI
/PRNewswire/ -- announces that purchasers or acquirers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between and , inclusive (the "Class Period") have until to seek appointment as lead plaintiff in the class action lawsuit.  The class acti...
PR Newswire - PRF · 09/11 13:10
SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
/PRNewswire/ --  announces that purchasers and acquirers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between and , inclusive (the "Class Period") have until to seek appointment as lead plaintiff in the class action lawsuit.  The class ac...
PR Newswire - PRF · 09/08 03:01
--B. Riley Lowers Spectrum Pharmaceuticals' PT to $6 from $8 on 'Disappointing' ROLONTIS Complete Response Letter, Keeps Buy Rating
MT Newswires · 08/18 09:48
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SPPI. Analyze the recent business situations of Spectrum Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SPPI stock price target is 6.20 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 250
Institutional Holdings: 109.08M
% Owned: 66.48%
Shares Outstanding: 164.07M
TypeInstitutionsShares
Increased
66
8.10M
New
23
884.29K
Decreased
33
5.32M
Sold Out
12
994.98K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Non-Executive Chairman/Independent Director
William Ashton
President/Chief Executive Officer/Director
Joseph Turgeon
Chief Financial Officer/Executive Vice President
Kurt Gustafson
Chief Operating Officer/Executive Vice President
Thomas Riga
Executive Vice President
Francois Lebel
Senior Vice President/Secretary
Keith Mcgahan
Independent Director
Nora Brennan
Independent Director
Seth Fischer
Independent Director
Jeffrey Vacirca
Independent Director
Dolatrai Vyas
Independent Director
Bernice Welles
Declaration Date
Dividend Per Share
Ex-Div Date
12/10/2012
Dividend USD 0.15
12/18/2012
About SPPI
Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company operates through developing and commercializing oncology and hematology drug products segment. It focuses on developing ROLONTIS and POZIOTINIB. ROLONTIS is being investigated for the treatment of chemotherapy-induced neutropenia. POZIOTINIB is an oral pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR, HER) Family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.

Webull offers kinds of Spectrum Pharmaceuticals, Inc. stock information, including NASDAQ:SPPI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPPI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SPPI stock methods without spending real money on the virtual paper trading platform.